Date:3/3/2010

303)d (333)d (684)g (177)g - (665)f Depreciation and amortiz- ation 8,406 (7,612)e 794 8,421 (7,460)e 961 Write-down of assets held for sale 3,090 (3,090)i - 1,283 (1,283)i - Write-down of goodwill - - - 50,285 (50,285)i - ------------------------------------------------------------------------- 71,577 (13,089) 58,488 115,489 (62,224) 53,265 ------------------------------------------------------------------------- Operating income (loss) (8,016) 13,036 5,020 (53,407) 61,872 8,465 ------------------------------------------------------------------------- Other income (expenses): Foreign exchange (loss) gain (385) 385 h - (1,032) 1,032 h - Investment and other income (loss) 304 288 j 92 (498) 544 j 46 (500)c Interest expense on long-term debt (9,068) 712 f (8,356) (10,639) 559 f (10,080) Write-down/ loss on investments - - - (10,964) 10,964 i - Write-down and other deferred financing charges - - - (3,000) 3,000 f - ------------------------------------------------------------------------- (9,149) 885 (8,264) (26,133) 16,099 (10,034) ------------------------------------------------------------------------- (Loss) income before income taxes (17,165) 13,921 (3,244) (79,540) 77,971 (1,569) Income tax expense (recovery) (1,532) 3,016 l 1,484 (2,577
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter